vs
亚什兰（ASH）与Ascendis Pharma A/S（ASND）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是Ascendis Pharma A/S的1.4倍（$386.0M vs $267.3M），Ascendis Pharma A/S同比增速更快（42.3% vs -4.7%），过去两年Ascendis Pharma A/S的营收复合增速更高（60.7% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
ASH vs ASND — 直观对比
营收规模更大
ASH
是对方的1.4倍
$267.3M
营收增速更快
ASND
高出47.0%
-4.7%
两年增速更快
ASND
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $267.3M |
| 净利润 | $-12.0M | — |
| 毛利率 | 27.2% | 90.5% |
| 营业利润率 | -1.6% | — |
| 净利率 | -3.1% | — |
| 营收同比 | -4.7% | 42.3% |
| 净利润同比 | 92.7% | — |
| 每股收益（稀释后） | $-0.26 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHASND
| Q4 25 | $386.0M | $267.3M | ||
| Q3 25 | $477.0M | $230.7M | ||
| Q2 25 | $463.0M | $170.7M | ||
| Q1 25 | $479.0M | $109.0M | ||
| Q4 24 | $405.0M | $187.8M | ||
| Q3 24 | $521.0M | $62.5M | ||
| Q2 24 | $544.0M | $38.9M | ||
| Q1 24 | $575.0M | $103.6M |
净利润ASHASND
| Q4 25 | $-12.0M | — | ||
| Q3 25 | $31.0M | $-65.9M | ||
| Q2 25 | $-742.0M | $-42.0M | ||
| Q1 25 | $31.0M | $-102.2M | ||
| Q4 24 | $-165.0M | — | ||
| Q3 24 | $17.0M | $-107.1M | ||
| Q2 24 | $6.0M | $-118.1M | ||
| Q1 24 | $120.0M | $-141.5M |
毛利率ASHASND
| Q4 25 | 27.2% | 90.5% | ||
| Q3 25 | 33.3% | 89.5% | ||
| Q2 25 | 28.5% | 80.1% | ||
| Q1 25 | 30.7% | 82.6% | ||
| Q4 24 | 27.4% | 91.9% | ||
| Q3 24 | 33.2% | 80.6% | ||
| Q2 24 | 34.2% | 68.2% | ||
| Q1 24 | 28.0% | 92.1% |
营业利润率ASHASND
| Q4 25 | -1.6% | — | ||
| Q3 25 | 12.8% | 5.1% | ||
| Q2 25 | -152.9% | -33.5% | ||
| Q1 25 | 10.6% | -103.2% | ||
| Q4 24 | -44.2% | — | ||
| Q3 24 | 6.1% | -167.3% | ||
| Q2 24 | -11.2% | -370.2% | ||
| Q1 24 | 3.7% | -51.2% |
净利率ASHASND
| Q4 25 | -3.1% | — | ||
| Q3 25 | 6.5% | -28.5% | ||
| Q2 25 | -160.3% | -24.6% | ||
| Q1 25 | 6.5% | -93.7% | ||
| Q4 24 | -40.7% | — | ||
| Q3 24 | 3.3% | -171.5% | ||
| Q2 24 | 1.1% | -303.9% | ||
| Q1 24 | 20.9% | -136.6% |
每股收益（稀释后）ASHASND
| Q4 25 | $-0.26 | — | ||
| Q3 25 | $0.83 | — | ||
| Q2 25 | $-16.21 | — | ||
| Q1 25 | $0.65 | — | ||
| Q4 24 | $-3.50 | — | ||
| Q3 24 | $0.34 | — | ||
| Q2 24 | $0.12 | — | ||
| Q1 24 | $2.39 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $665.3M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $1.9B | $-175.8M |
| 总资产 | $4.5B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资ASHASND
| Q4 25 | $304.0M | $665.3M | ||
| Q3 25 | $215.0M | $582.2M | ||
| Q2 25 | $207.0M | $533.6M | ||
| Q1 25 | $168.0M | $559.4M | ||
| Q4 24 | $219.0M | $604.3M | ||
| Q3 24 | $300.0M | $675.6M | ||
| Q2 24 | $399.0M | $279.4M | ||
| Q1 24 | $439.0M | $345.9M |
总债务ASHASND
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
股东权益ASHASND
| Q4 25 | $1.9B | $-175.8M | ||
| Q3 25 | $1.9B | $-188.0M | ||
| Q2 25 | $1.9B | $-202.6M | ||
| Q1 25 | $2.6B | $-205.0M | ||
| Q4 24 | $2.6B | $-114.2M | ||
| Q3 24 | $2.9B | $-105.1M | ||
| Q2 24 | $3.0B | $-346.8M | ||
| Q1 24 | $3.1B | $-257.2M |
总资产ASHASND
| Q4 25 | $4.5B | $1.4B | ||
| Q3 25 | $4.6B | $1.2B | ||
| Q2 25 | $4.6B | $1.2B | ||
| Q1 25 | $5.2B | $1.1B | ||
| Q4 24 | $5.2B | $1.3B | ||
| Q3 24 | $5.6B | $1.2B | ||
| Q2 24 | $5.7B | $819.0M | ||
| Q1 24 | $5.9B | $866.7M |
负债/权益比ASHASND
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.42× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $58.2M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | — |
| 自由现金流率自由现金流/营收 | 28.8% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $200.0M | — |
8季度趋势，按日历期对齐
经营现金流ASHASND
| Q4 25 | $125.0M | $58.2M | ||
| Q3 25 | $40.0M | — | ||
| Q2 25 | $115.0M | — | ||
| Q1 25 | $9.0M | $-15.5M | ||
| Q4 24 | $-30.0M | $-330.7M | ||
| Q3 24 | $80.0M | — | ||
| Q2 24 | $127.0M | — | ||
| Q1 24 | $54.0M | $-109.7M |
自由现金流ASHASND
| Q4 25 | $111.0M | — | ||
| Q3 25 | $6.0M | — | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $-12.0M | — | ||
| Q4 24 | $-53.0M | — | ||
| Q3 24 | $42.0M | — | ||
| Q2 24 | $98.0M | — | ||
| Q1 24 | $20.0M | — |
自由现金流率ASHASND
| Q4 25 | 28.8% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 20.5% | — | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | -13.1% | — | ||
| Q3 24 | 8.1% | — | ||
| Q2 24 | 18.0% | — | ||
| Q1 24 | 3.5% | — |
资本支出强度ASHASND
| Q4 25 | 3.6% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 5.3% | — | ||
| Q1 24 | 5.9% | — |
现金转化率ASHASND
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | — | ||
| Q1 24 | 0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
ASND
暂无分部数据
